Angina drug ranolazine useful against center rhythm disorders potentially A recently approved angina drug may also represent a powerful new treatment for a rare hereditary syndrome that places teenagers at risk for sudden cardiac loss of life, according to analyze presented on April 1st at the 57th Annual Scientific Classes of the American University of Cardiology in Chicago. Cardiac arrhythmias are electric malfunctions that throw the center out of rhythm, causing most of the 330,000 sudden cardiac deaths every year in the usa.Piper Cancer tumor Center at Scottsdale Healthcare was the business lead site in the 2- – year pilot study. In addition, patients in the analysis were treated at Virginia Tumor Specialists, US Oncology, in Fairfax, Vir.; and at Evergreen Hematology & Oncology in Spokane, Wash. Translational Drug Development , a TGen business, managed the pilot scientific trial, and can also oversee the follow-on study, Side-Out II. This is an exciting research for TD2, stated Linda Vocila, BSN, RN, Director of Clinical Operations at TD2 and co-author of the study.